Highlight
The APERITIF trial evaluated the efficacy of adding very low-dose rivaroxaban (2.5 mg twice daily) to dual antiplatelet therapy (DAPT) for the prevention of left ventricular (LV) thrombus in patients following anterior ST-segment elevation myocardial infarction (STEMI).
Primary results showed that LV thrombus occurred in 13.7% of the rivaroxaban group compared to 16.6% in the DAPT-only group, a difference that was not statistically significant (P = .34).
